

40년 역사의 Rx-pharma 제조 사업





40 Rx-pharma

이 판매 회사는 인도 방갈로르에 본사를 둔 의료 회사입니다. 이 사업은 전 세계 사람들에게 의약품 및 영양 보조제를 제조 및 공급하는 일에 관여합니다(WHO-GMP 및 ISO 인증에 의해 지정된 품질 표준).

이 사업은 ISO 9001을 완벽하게 갖추고 있으며 WHO GMP 인증 장치는 중앙 아메리카, 나이지리아, 방글라데시, 캄보디아, 스리랑카, 말레이시아, 도미니카 공화국 등과 같은 국가의 주문을 처리하고 있습니다. 정제, 캡슐 및 경구 액체의 생산.

회사는 제네릭, 기능식품 및 허브 의료 제품을 생산합니다.

재무 성과 하이라이트(3년)

수익은 지난 3년 동안 꾸준히 증가했지만 EBITDA는 감소했습니다. EBITDA의 감소는 5년 전에 시작된 온라인 브랜드의 광고 지출 증가로 인한 것입니다. 이 D2C 보충제 브랜드로 얻은 모든 이익은 브랜드 마케팅에 다시 사용되어 회사 전체의 EBITDA가 감소했습니다.

제품

제네릭 의약품에 따른 438개의 제조 라이선스. 이 중 회사는 현재 148개의 CoPP 승인을 보유하고 있어 여러 ROW 국가에서 제품을 수출하도록 등록할 수 있습니다.

압도적인 경쟁 우위

비용 이점이 있는 소규모 제조 시설을 위한 높은 생산 능력. 방갈로르 시 안에 위치한 제조 시설은 숙련된 노동력과 비숙련 노동력 모두에게 접근이 가능합니다.

TARGET PRICE

\$12,000,000

GROSS REVENUE

\$1,900,000

EBITDA

\$0

BUSINESS TYPE

제조업

ESTABLISHED

1982

SUPPORT & TRAINING

일년

REASON FOR SELLING

퇴직

COUNTRY

인도

BUSINESS ID

L#20210016

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM